Compare AGM & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | BHVN |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | United States |
| Employees | 212 | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | 2022 |
| Metric | AGM | BHVN |
|---|---|---|
| Price | $173.17 | $10.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 14 |
| Target Price | ★ $215.00 | $29.08 |
| AVG Volume (30 Days) | 68.2K | ★ 2.0M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | N/A | ★ 26.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.97 | N/A |
| Revenue Next Year | $12.21 | N/A |
| P/E Ratio | $9.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $136.57 | $7.48 |
| 52 Week High | $210.64 | $24.06 |
| Indicator | AGM | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 69.69 | 55.42 |
| Support Level | $173.42 | $9.41 |
| Resistance Level | $179.02 | $11.92 |
| Average True Range (ATR) | 4.12 | 0.65 |
| MACD | 2.27 | 0.17 |
| Stochastic Oscillator | 84.93 | 75.66 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven reportable segments: Farm & Ranch, which generates maximum revenue, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA. Geographically, the company's operations are spread across different regions in the United States.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.